Last reviewed · How we verify
Systane
At a glance
| Generic name | Systane |
|---|---|
| Also known as | polyethyleneglycol 400, propyleneglycol, hydroxypropyl guar, 1 to 2 drops of Systane® Gel Drops in each eye daily. |
| Sponsor | Innovative Medical |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- SYSTANE® PRO vs. MIEBO™ in Dry Eye Disease (PHASE4)
- Improved Efficacy of Selective Laser Trabeculoplasty With the Addition of Rocklatan Post-treatment vs Artificial Tears Post-treatment
- Comparison of Ocular Lubricants in People With Symptoms of Dry Eye (PHASE4)
- Preoperative iLux on Cataract Surgery Derived Dry Eye Disease Due to Meibomian Gland Dysfunction (NA)
- Optimizing the Ocular Surface With Systane COMPLETE Pre- and Post-operatively in Patients With Dry Eye Planning for Cataract Surgery: An Extension Study of Optimizing the Ocular Surface With Systane COMPLETE in Patients With Dry Eye Planning for Cataract Surgery (PHASE4)
- Optimizing the Ocular Surface With Systane COMPLETE in Patients With Dry Eye Planning for Cataract Surgery (PHASE4)
- Quantifying Ocular Surface Aberrations After Tear Film Interventions (PHASE4)
- Systane® Ultra Preservative Free Lubricant Eye Drops (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Systane CI brief — competitive landscape report
- Systane updates RSS · CI watch RSS
- Innovative Medical portfolio CI